June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–5.

Article  CAS  PubMed  Google Scholar 

Wei J, Guo Y, Wang Y, Wu Z, Bo J, Zhang B, et al. Clinical development of CAR T cell therapy in China: 2020 update. Cell Mol Immunol. 2021;18(4):792–804.

Article  CAS  PubMed  Google Scholar 

Labanieh L, Mackall CL. CAR immune cells: design principles, resistance and the next generation. Nature. 2023;614(7949):635–48.

Article  CAS  PubMed  Google Scholar 

Luo Y, Gao L, Liu J, Yang L, Wang L, Lai X, et al. Donor-derived Anti-CD19 CAR T cells GC007g for relapsed or refractory B-cell acute lymphoblastic leukemia after allogeneic HSCT: a phase 1 trial. EClinicalMedicine. 2024;67:102377.

Article  PubMed  Google Scholar 

Sun W, Liang A-B, Huang H, Huang X-J. Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience. Haematologica. 2023;108(8):2011–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mullard A. FDA approves fourth CAR-T cell therapy. Nat Rev Drug Discov. 2021;20(3):166.

PubMed  Google Scholar 

Hu Y, Feng J, Gu T, Wang L, Wang Y, Zhou L, et al. CAR T-cell therapies in China: rapid evolution and a bright future. Lancet Haematol. 2022;9(12):e930–41.

Article  CAS  PubMed  Google Scholar 

Chavez JC, Bachmeier C, Kharfan-Dabaja MA. CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. Ther Adv Hematol. 2019;10:2040620719841581.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mei H, Hari P, Hu Y. Exercise CALM and make CAR-T therapy work better. Sci Bull (Beijing). 2022;67(19):1925–8.

Article  PubMed  Google Scholar 

Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383(23):2255–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gust J, Hay KA, Hanafi L-A, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7(12):1404–19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang Y, Si X, Shao M, Teng X, Xiao G, Huang H. Rewiring mitochondrial metabolism to counteract exhaustion of CAR-T cells. J Hematol Oncol. 2022;15(1):38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu Y, An L, Huang R, Xiong J, Yang H, Wang X, et al. Strategies to enhance CAR-T persistence. Biomark Res. 2022;10(1):86.

Article  PubMed  PubMed Central  Google Scholar 

Bulliard Y, Andersson BS, Baysal MA, Damiano J, Tsimberidou AM. Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy. J Hematol Oncol. 2023;16(1):108.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lai P, Chen X, Wang Y, Wang J, Zhang Y, Geng S, et al. C3aR costimulation enhances the antitumor efficacy of CAR-T cell therapy through Th17 expansion and memory T cell induction. J Hematol Oncol. 2022;15(1):68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mazinani M, Rahbarizadeh F. CAR-T cell potency: from structural elements to vector backbone components. Biomark Res. 2022;10(1):70.

Article  PubMed  PubMed Central  Google Scholar 

Shimabukuro-Vornhagen A, Böll B, Schellongowski P, Valade S, Metaxa V, Azoulay E, et al. Critical care management of chimeric antigen receptor T-cell therapy recipients. CA Cancer J Clin. 2022;72(1):78–93.

Article  PubMed  Google Scholar 

Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales M-A, Ghobadi A, et al. Survival with Axicabtagene Ciloleucel in large B-Cell lymphoma. N Engl J Med. 2023;389(2):148–57.

Article  CAS  PubMed  Google Scholar 

Locke FL, Miklos DB, Jacobson CA, Perales M-A, Kersten M-J, Oluwole OO, et al. Axicabtagene Ciloleucel as Second-Line therapy for large B-Cell lymphoma. N Engl J Med. 2022;386(7):640–54.

Article  CAS  PubMed  Google Scholar 

Ajina A, Maher J. Strategies to address chimeric Antigen receptor Tonic Signaling. Mol Cancer Ther. 2018;17(9):1795–815.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21(6):581–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen J, Qiu S, Li W, Wang K, Zhang Y, Yang H, et al. Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness. Cell Res. 2023;33(5):341–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Teng F, Cui T, Zhou L, Gao Q, Zhou Q, Li W. Programmable synthetic receptors: the next-generation of cell and gene therapies. Signal Transduct Target Ther. 2024;9(1):7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Di Stasi A, Tey S-K, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365(18):1673–83.

Article  PubMed  PubMed Central  Google Scholar 

Diaconu I, Ballard B, Zhang M, Chen Y, West J, Dotti G, et al. Inducible Caspase-9 selectively modulates the toxicities of CD19-Specific chimeric Antigen receptor-modified T cells. Mol Ther. 2017;25(3):580–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mestermann K, Giavridis T, Weber J, Rydzek J, Frenz S, Nerreter T et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Sci Transl Med. 2019; 11(499).

Cao W, Geng ZZ, Wang N, Pan Q, Guo S, Xu S, et al. A reversible Chemogenetic switch for Chimeric Antigen Receptor T Cells. Angew Chem Int Ed Engl. 2022;61(10):e202109550.

Article  CAS  PubMed  Google Scholar 

Wu Y, Liu Y, Huang Z, Wang X, Jin Z, Li J, et al. Control of the activity of CAR-T cells within tumours via focused ultrasound. Nat Biomed Eng. 2021;5(11):1336–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Smole A, Benton A, Poussin MA, Eiva MA, Mezzanotte C, Camisa B et al. Expression of inducible factors reprograms CAR-T cells for enhanced function and safety. Cancer Cell. 2022; 40(12).

Huang Z, Wu Y, Allen ME, Pan Y, Kyriakakis P, Lu S, et al. Engineering light-controllable CAR T cells for cancer immunotherapy. Sci Adv. 2020;6(8):eaay9209.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li H-S, Wong NM, Tague E, Ngo JT, Khalil AS, Wong WW. High-performance multiplex drug-gated CAR circuits. Cancer Cell. 2022; 40(11).

Qi J, Tsuji K, Hymel D, Burke TR, Hudecek M, Rader C, et al. Chemically programmable and switchable CAR-T therapy. Angew Chem Int Ed Engl. 2020;59(29):12178–85.

Article  CAS  PubMed  PubMed Central